Community level evaluation of adenoid hypertrophy on the basis of symptom scoring and its X-ray correlation

Dixit, Yogita; Tripathi, Prem Siddharth

doi:10.4103/2249-4863.201156

Cited by 11 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It causes nasal obstruction, mouth breathing, restlessness and contamination of the ear and sinuses. In the absence of infection, adenoid tissue typically relapses over time 21 . It is widely accepted that adenoidectomy is the best treatment for adenoid hypertrophy, although complications such as haemorrhage, infections and palate dysfunction can occur following the procedure and the hazards of general anaesthesia 18 .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of montelukast for adenoid hypertrophy in paediatrics: A systematic review and meta‐analysis

Alanazi,

Alruwaili,

Alanazy

et al. 2024

Clinical Otolaryngology

View full text Add to dashboard Cite

IntroductionLeukotrienes play a significant role in the pathogenesis of adenoid hypertrophy (A.H.). Therefore, we aimed to analyse the role of montelukast, a leukotriene receptor antagonist, alone or in combination with mometasone, a potent local intranasal steroid, for the treatment of A.H.MethodsParticipants were children with A.H. were treated with montelukast alone or montelukast and mometasone furoate. The main outcome measures were effect of montelukast on clinical symptoms of A.H. A literature review was conducted using online search engines, Cochrane Library, PubMed, Web of Science and Scopus, for randomized clinical trials assessing children with A.H. treated with montelukast alone or montelukast and mometasone furoate. Seven randomized clinical trials (RCTs) were included with 742 children.ResultsOur study reveals that montelukast alone or in combination with intranasal mometasone furoate significantly improves clinical symptoms of adenoid hypertrophy such as snoring, sleeping disturbance, mouth breathing and A/N ratio. Montelukast was superior to placebo in decreasing snoring (SMD = −1.00, 95% CI [−1.52, −0.49]), sleep discomfort (SMD = −1.26, 95% CI [−1.60, −0.93]), A/N ratio (MD = −0.11, 95% CI [−0.14, −0.09]) and mouth breathing (SMD = −1.36, 95% CI [−1.70, −1.02]). No difference was detected between montelukast and mometasone versus mometasone alone in snoring (SMD = −0.21, 95%CI [−0.69, 0.27]); however, the combination group was superior to the mometasone alone in mouth breathing (SMD = −0.46, 95% CI [−0.73, −0.19]).ConclusionsThe limitation of studies included a small sample size, with an overall low to medium quality. Thus, further larger, higher‐quality RCTs are recommended to provide more substantial evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of montelukast for adenoid hypertrophy in paediatrics: A systematic review and meta‐analysis

Alanazi,

Alruwaili,

Alanazy

et al. 2024

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

“…Chronic or recurrent infections are the two most common manifestations of pathologic and physiologic changes in the adenoids. If infection does not occur, adenoid tissue can regress in the process of time (22). It leads to symptoms including nasal obstruction, oral breathing, sleep disturbances, infections in the ear and sinuses, and reduced quality of life.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data

Tuhanioğlu¹,

Erkan²

2017

Turk J Med Sci

View full text Add to dashboard Cite

IntroductionAdenoids are pyramid-shaped enlarged masses of lymphoid tissue in the nasopharynx (1), and they form an important part of Waldeyer's tonsillar ring. Although the adenoids are very small at birth, they may exhibit growth in the first 4 years of life, depending on the development of the immune system (2).The incidence of adenoid hypertrophy is 2%-3% in children (2). Untreated adenoid hypertrophy may lead to difficulty in breathing through the nose, snoring, sleep apnea, nasal speech, ear problems, growth retardation, and craniofacial anomalies (1,2). Various methods are used for the diagnosis of adenoid hypertrophy including lateral head radiography, videofluoroscopy, palpation, and nasal endoscopy; the most recent methods are lateral radiographs and nasal endoscopy (3).Adenoidectomy is a commonly performed procedure in children that may cause complications such as early or late bleeding (4%-5%), adenoid tissue recurrence (10%-20%), and postoperative respiratory problems (27%) (2). In addition, anesthesia risks are also among the factors that should be taken into account (4). As such, medical therapy alternatives to adenoidectomy are important and must be tried before surgery.Leukotrienes are inflammatory mediators found in the respiratory system and these play a role in several allergic childhood diseases (5). Cysteinyl leukotriene receptor-1 mediates the inflammatory pathway and has been found in high rates in postoperative adenotonsillar tissues in pediatric patients with obstructive sleep apnea (6-8). Montelukast is an effective and reliable cysteinyl leukotriene receptor antagonist that can be used in oral form and has high bioavailability. It was approved by the United States Food and Drug Administration (FDA) for preventive therapy against the inflammatory component in asthma and allergic rhinitis in children aged over 1 year. Background/aim: The incidence of adenoid hypertrophy is 2%-3% in children. Adenoidectomy is a commonly performed procedure in children that may cause complications such as early or late bleeding (4%-5%), recurrence of adenoid tissue (10%-20%), and postoperative respiratory problems (27%). Therefore, medical therapy alternatives to adenoidectomy are important and must be tried before surgery. In this study, we investigated the efficacy of mometasone furoate, montelukast, and a combination of these drugs in pediatric patients with adenoid hypertrophy who were scheduled for reduction with medical therapy after not being recommended for surgery. Materials and methods:The study included 120 children with adenoid hypertrophy aged between 4 and 10 years. The patients were randomized into 4 separate groups, with 30 in each group. Group 1 received 100 µg of mometasone furoate per day, group 2 received 4/5 mg (for age) montelukast per day, and group 3 received mometasone furoate + montelukast. Medical therapy continued for 3 months in the treatment groups. Group 4, which comprised patients with mild symptoms, received no treatment and was the control group. The pre-and posttreatment ...

show abstract

“…Among these, Choudhari and Shrivastav in a recent study, found the methods proposed by Holmberg and Linder-Aronson and Maw et al to have better diagnostic accuracy due to their high sensitivity and specificity [108]. Adenoidnasopharyngeal (A/N) ratio has also been used to assess adenoid size in several AH studies [23,53,[122][123][124][125], proposed earlier by Fujioka et al [126]. These studies used lateral X-rays/cephalograms and found a positive correlation between adenoid size and severity of AH symptoms.…”

Section: Techniques For Diagnosis 61 Adenoid Hypertrophymentioning

confidence: 99%

The Link Between Adenoids and Nasopharyngeal Carcinoma

Asante¹,

Akakpo²,

Wiafe³

2023

Tonsils and Adenoids

View full text Add to dashboard Cite

Adenoids, play a significant role in inflammatory response, especially in children. Together with other tissues of the lymphatic system, it fights off infections. In most cases of nasopharyngeal cancer, though rare, other histopathological variants of adenoids are seen. Adenoid hypertrophy is mostly observed, which causes obstruction of the nasopharynx and dysfunction of the Eustachian tube because of the formation of an abnormal tissue mass. Different viral and bacterial pathogens are associated with adenoid hypertrophy, including Epstein-Barr virus (EBV), coronavirus, parainfluenza virus, Mycoplasma pneumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae. Among these, EBV is associated with both adenoid hypertrophy and nasopharyngeal cancer, indicating the effect of EBV on both nasopharyngeal cancer and adenoids. We critically appraise the current evidence and discuss potential link between adenoids and nasopharyngeal carcinoma.

show abstract

Community level evaluation of adenoid hypertrophy on the basis of symptom scoring and its X-ray correlation

Cited by 11 publications

References 6 publications

Efficacy of montelukast for adenoid hypertrophy in paediatrics: A systematic review and meta‐analysis

Efficacy of montelukast for adenoid hypertrophy in paediatrics: A systematic review and meta‐analysis

Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data

The Link Between Adenoids and Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About